GW Pharmaceuticals plc, of London, said it intends to sell $300 million of American depositary shares (ADSs) representing ordinary shares of GW on Nasdaq in an underwritten U.S. public offering. The underwriters will be granted a 30-day option to purchase up to an additional $45 million of ADSs at the offering price.